These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 34963563)

  • 1. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
    Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
    Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
    BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
    Zhang J; Huang M; Cai Y; Wang L; Xiao J; Lan P; Hu H; Wu X; Ling J; Peng J; Chen D; Kang L; Zhang Y; Ren D; Wang H; Chen S; Lin F; Zheng J; Zhou Z; Wang J; Deng Y
    Clin Colorectal Cancer; 2019 Dec; 18(4):238-244. PubMed ID: 31378655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
    Ye W; Shi L; Qian L; Sun Y; Sun X
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1188. PubMed ID: 32721108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study.
    Zhou J; Huang J; Zhou Z; Deng X; Wu Q; Wang Z
    Int J Colorectal Dis; 2024 Mar; 39(1):38. PubMed ID: 38492080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Analysis of the Efficacy and Safety of Different Neoadjuvant Strategies in the Treatment of Locally Advanced Rectal Cancer.
    Chen W; Wang W; Huang S; Zhou L; Wang G; Chen W
    Cancer Invest; 2024 Jul; ():1-10. PubMed ID: 39037150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single-institution study with propensity score-matched comparative analysis.
    Sun XY; Cai SH; Xu L; Luo D; Qiu HZ; Wu B; Lin GL; Lu JY; Zhang GN; Xiao Y
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):142-149. PubMed ID: 32031326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of neoadjuvant CapeOX/mFOLFOX6 without radiation for patients with baseline resectable mid-low locally advanced rectal cancer.
    Zhao X; He ZR; Han PY; Cai ZH; Fu ZW; Zhang LY; Sun J; Ma JJ; Dong F; Zang L; Zheng MH
    J Dig Dis; 2022 Dec; 23(12):695-704. PubMed ID: 36661868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation.
    Wu J; Huang M; Wu Y; Hong Y; Cai L; He R; Luo Y; Wang P; Huang M; Lin J
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8897-8912. PubMed ID: 37154929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Preoperative Transcatheter Rectal Arterial Chemoembolisation in Patients with Locally Advanced Rectal Cancer: Results from a Prospective, Phase II PCAR Trial.
    Yang W; Qian C; Luo J; Chen C; Feng Y; Dai N; Li X; Xiao H; Yang Y; Li M; Li C; Wang D
    Clin Oncol (R Coll Radiol); 2024 Apr; 36(4):233-242. PubMed ID: 38342657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
    Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
    BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies.
    Zhang J; Xie X; Wu Z; Hu H; Cai Y; Li J; Ling J; Ding M; Li W; Deng Y
    Clin Colorectal Cancer; 2021 Dec; 20(4):e240-e248. PubMed ID: 34334298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
    In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study.
    Li A; Huang T; Zheng R; Chi P; Li Z; Wang X; Xu B
    BMC Cancer; 2022 Jul; 22(1):789. PubMed ID: 35850711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 17. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
    Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
    Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncologic and survival outcomes in elderly patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy and total mesorectal excision.
    He F; Chen M; Xiao WW; Zhang Q; Liu Y; Zheng J; Wan XB; Gao YH
    Jpn J Clin Oncol; 2021 Aug; 51(9):1391-1399. PubMed ID: 34155513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection for Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncologic Outcomes: A Propensity Score-Matched Analysis.
    Yamaguchi T; Akiyoshi T; Fukunaga Y; Sakamoto T; Mukai T; Hiyoshi Y; Nagasaki T; Taguchi S; Chino A; Shinozaki E; Yamaguchi K; Konishi T
    Ann Surg Oncol; 2023 Aug; 30(8):4716-4724. PubMed ID: 37032405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.